ArticleFrontiers in microbiology2016
The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Dose Optimization of Tilmicosin againstJournal of agricultural and food chemistry · 2026Article
- A marker-free genetic manipulation method for Glaesserella parasuis strains developed by alternately culturing transformants at 37°C and 30°C.BMC biotechnology · 2024Article
- Pharmacokinetic/pharmacodynamic integration of tilmicosin againstFrontiers in veterinary science · 2023Article
- Optimal Regimens and Clinical Breakpoint of Avilamycin AgainstFrontiers in pharmacology · 2022Article
- Article
- Determination of Susceptibility Breakpoint for Cefquinome againstAntibiotics (Basel, Switzerland) · 2021Article
- Exploration of Clinical Breakpoint of Danofloxacin forAntibiotics (Basel, Switzerland) · 2021Article
- Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China.Pathogens (Basel, Switzerland) · 2021Article
- Prudent Use of Tylosin for Treatment ofFrontiers in microbiology · 2021Article
- Facile Preparation of Tilmicosin-Loaded Polymeric Nanoparticle with Controlled Properties and Functions.ACS omega · 2020Article
- Solid Lipid Nanoparticles for Duodenum Targeted Oral Delivery of Tilmicosin.Pharmaceutics · 2020Article
- The PK/PD Integration and Resistance of Tilmicosin againstPathogens (Basel, Switzerland) · 2020Article
- Computational Approaches in Preclinical Studies on Drug Discovery and Development.Frontiers in chemistry · 2020Review
- Susceptibility breakpoint for Danofloxacin against swine Escherichia coli.BMC veterinary research · 2019Article
- Article
- The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin againstOncotarget · 2018Article
- PK-PD Integration Modeling and Cutoff Value of Florfenicol againstFrontiers in pharmacology · 2018Article
- Optimal Regimens and Cutoff Evaluation of Tildipirosin AgainstFrontiers in pharmacology · 2018Article
- Basic Characterization of Natural Transformation in a Highly TransformableFrontiers in cellular and infection microbiology · 2018Article
- Pharmacokinetics of tilmicosin in healthy pigs and in pigs experimentally infected withJournal of veterinary science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to establish antimicrobial susceptibility breakpoints for tilmicosin against Haemophilus parasuis, which is an important pathogen of respiratory tract infections. The minimum inhibitory concentrations (MICs) of 103 H. parasuis isolates were determined by the agar dilution method. The wild type (WT) distribution and epidemiologic cutoff value (ECV) were evaluated by statistical analysis. The new bronchoaveolar lavage was used to establish intrapulmonary pharmacokinetic (PK) model in swine. The pharmacokinetic (PK) parameters of tilmicosin, both in pulmonary epithelial lining fluid (PELF) and in plasma, were determined using high performance liquid chromatography method and WinNonlin software. The pharmacodynamic cutoff (COPD) was calculated using Monte Carlo simulation. Our results showed that 100% of WT isolates were covered when the ECV was set at 16 μg/mL. The tilmicosin had concentration-dependent activity against H. parasuis. The PK data indicated that tilmicosin concentrations in PELF was rapidly increased to high levels at 4 h and kept stable until 48 h after drug administration, while the tilmicosin concentration in plasma reached maximum levels at 4 h and continued to decrease during 4-72 h. Using Monte Carlo simulation, COPD was defined as 1 μg/mL. Conclusively, the ECV and COPD of tilmicosin against H. parasuis were established for the first time based on the MIC distribution and PK-PD analysis in the target tissue, respectively. These values are of great importance for detection of tilmicosin-resistant H. parasuis and for effective treatment of clinical intrapulmonary infection caused by H. parasuis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.